The subsidiary has been incorporated with an initial share capital of CLP 1,000,000 (approximately USD 1,050), divided into 100 shares with a nominal value of CLP 10,000 each. Eugia Pharma B.V. has subscribed to 100% of the share capital in cash, thereby holding full ownership of the Chilean entity.
Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.
The company’s consolidated net profit tumbled 10.3% to Rs 824.75 crore despite a 4.5% increase in revenue from operations to Rs 7791.77 crore in Q1 FY26 over Q1 FY25.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."